Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials

Research output: Contribution to journalArticle

Abstract

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality worldwide and despite some advances in therapy the overall prognosis remains disappointing. New therapeutic approaches like vaccination have been proposed and several clinical trials are ongoing.Many tumor antigens have been identified so far and specific tumor vaccines targeting these antigens have been developed. Even if the ideal setting for vaccine therapy might be the adjuvant one, vaccines seem to be potentially beneficial also in advanced disease and combination therapy could be a promising treatment option.In the advanced setting anti-MUC-1 vaccine (belagenpumatucel) and anti-TGF-β2 vaccine (BPL-25) have entered in phase III trials as maintenance therapy after first line chemotherapy. In the adjuvant setting the most relevant and promising vaccines are directed against MAGE-A3 and PRAME, respectively.We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC.

Original languageEnglish
Pages (from-to)432-443
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Vaccines
Clinical Trials
Active Immunotherapy
Therapeutics
Cancer Vaccines
Neoplasm Antigens
Vaccination
Antigens
Drug Therapy
Mortality
Neoplasms

Keywords

  • Adjuvant vaccines
  • Non-small cell lung cancer
  • Tumor antigens
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{66e8e2435f004633934eb029f8461418,
title = "Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials",
abstract = "Non-small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality worldwide and despite some advances in therapy the overall prognosis remains disappointing. New therapeutic approaches like vaccination have been proposed and several clinical trials are ongoing.Many tumor antigens have been identified so far and specific tumor vaccines targeting these antigens have been developed. Even if the ideal setting for vaccine therapy might be the adjuvant one, vaccines seem to be potentially beneficial also in advanced disease and combination therapy could be a promising treatment option.In the advanced setting anti-MUC-1 vaccine (belagenpumatucel) and anti-TGF-β2 vaccine (BPL-25) have entered in phase III trials as maintenance therapy after first line chemotherapy. In the adjuvant setting the most relevant and promising vaccines are directed against MAGE-A3 and PRAME, respectively.We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC.",
keywords = "Adjuvant vaccines, Non-small cell lung cancer, Tumor antigens, Vaccine therapy",
author = "{De Pas}, Tommaso and Monica Giovannini and Maria Rescigno and Chiara Catania and Francesca Toffalorio and Gianluca Spitaleri and Angelo Delmonte and Massimo Barberis and Lorenzo Spaggiari and Piergiorgio Solli and Giulia Veronesi and {De Braud}, Filippo",
year = "2012",
month = "9",
doi = "10.1016/j.critrevonc.2011.12.005",
language = "English",
volume = "83",
pages = "432--443",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Vaccines in non-small cell lung cancer

T2 - Rationale, combination strategies and update on clinical trials

AU - De Pas, Tommaso

AU - Giovannini, Monica

AU - Rescigno, Maria

AU - Catania, Chiara

AU - Toffalorio, Francesca

AU - Spitaleri, Gianluca

AU - Delmonte, Angelo

AU - Barberis, Massimo

AU - Spaggiari, Lorenzo

AU - Solli, Piergiorgio

AU - Veronesi, Giulia

AU - De Braud, Filippo

PY - 2012/9

Y1 - 2012/9

N2 - Non-small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality worldwide and despite some advances in therapy the overall prognosis remains disappointing. New therapeutic approaches like vaccination have been proposed and several clinical trials are ongoing.Many tumor antigens have been identified so far and specific tumor vaccines targeting these antigens have been developed. Even if the ideal setting for vaccine therapy might be the adjuvant one, vaccines seem to be potentially beneficial also in advanced disease and combination therapy could be a promising treatment option.In the advanced setting anti-MUC-1 vaccine (belagenpumatucel) and anti-TGF-β2 vaccine (BPL-25) have entered in phase III trials as maintenance therapy after first line chemotherapy. In the adjuvant setting the most relevant and promising vaccines are directed against MAGE-A3 and PRAME, respectively.We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC.

AB - Non-small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality worldwide and despite some advances in therapy the overall prognosis remains disappointing. New therapeutic approaches like vaccination have been proposed and several clinical trials are ongoing.Many tumor antigens have been identified so far and specific tumor vaccines targeting these antigens have been developed. Even if the ideal setting for vaccine therapy might be the adjuvant one, vaccines seem to be potentially beneficial also in advanced disease and combination therapy could be a promising treatment option.In the advanced setting anti-MUC-1 vaccine (belagenpumatucel) and anti-TGF-β2 vaccine (BPL-25) have entered in phase III trials as maintenance therapy after first line chemotherapy. In the adjuvant setting the most relevant and promising vaccines are directed against MAGE-A3 and PRAME, respectively.We will review the key points for effective active immunotherapies and combination therapies, giving an update on the most promising vaccines developed in NSCLC.

KW - Adjuvant vaccines

KW - Non-small cell lung cancer

KW - Tumor antigens

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=84864935156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864935156&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.12.005

DO - 10.1016/j.critrevonc.2011.12.005

M3 - Article

C2 - 22366114

AN - SCOPUS:84864935156

VL - 83

SP - 432

EP - 443

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -